References
1. Bercovitz RS, Josephson CD. Thrombocytopenia and bleeding in pediatric oncology patients. Hematology Am Soc Hematol Educ Program. 2012;2012:499-505.
2. Cairo MS. Dose reductions and delays: limitations of myelosuppressive chemotherapy. Oncology (Williston Park). 2000;14(9 Suppl 8):21-31.
3. Al-Samkari H. Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem. Hematology. 2022;2022(1):286-295.
4. Degliuomini MD, Armstrong K, Mauguen A, et al. Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for intervention. Pediatr Blood Cancer. 2022;69(10):e29776.
5. Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45-54.
6. Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649-1658.
7. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. New England Journal of Medicine. 2017;376(16):1540-1550.
8. Nagrebetsky A, Al-Samkari H, Davis N, Kuter D, Wiener-Kronish J. Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. British Journal of Anaesthesia. 2019;122(1):19-31.
9. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C.New England Journal of Medicine. 2007;357(22):2227-2236.
10. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403.
11. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. New England Journal of Medicine. 2010;363(20):1889-1899.
12. Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.Haematologica. 2021;106(4):1148-1157.
13. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology. 2015;29(4):282-282.
14. Soff GA, Miao Y, Bendheim G, et al. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. J Clin Oncol. 2019;37(31):2892-2898.
15. Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Supportive care in cancer. 2014;22:1217-1222.
16. Mingot-Castellano ME, Reguera-Ortega JL, Zafra Torres D, et al. Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients. J Clin Med. 2024;13(17).
17. Beyar-Katz O, Perry C, On YB, et al. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience. Ann Hematol. 2022;101(8):1769-1776.
18. Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017;64(8).
19. Merjaneh N, Young J, Mangoli A, et al. Chemotherapy-induced thrombocytopenia in Ewing sarcoma: Implications and potential for romiplostim supportive care. Pediatr Blood Cancer. 2022;69(7):e29548.
20. Fassel H, Bussel JB, Roberts SS, Modak S. Romiplostim for immune thrombocytopenia in neuroblastoma patients receiving chemotherapy.Journal of pediatric hematology/oncology. 2019;41(4):e257-e259.
21. Griffiths EA, Roy V, Alwan L, et al. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2022;20(5):436-442.
22. National Institutes of Health NCICTCfAECvhccgpeadCv.
23. Cheng THT, Tsui TKC, Kwok JSS, et al. Comprehensive characterization and resolution of discrepant spectrophotometric bilirubin results in patients on eltrombopag therapy. Clinical Chemistry and Laboratory Medicine (CCLM). 2020;58(10):1713-1723.
24. Poventud-Fuentes I, Garnett E, Despotovic J, Devaraj S. Interference of eltrombopag with bilirubin measurements on the Vitros 5600 analyzer.J Clin Lab Anal. 2021;35(8):e23796.
25. Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2018;5(1):e34-e43.
26. Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.Cancer. 2014;120(12):1838-1846.
27. Corazza F, Hermans C, D’Hondt S, et al. Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia.Blood. 2006;107(6):2525-2530.
28. Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.Blood. 2009;114(18):3899-3908.
29. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010;28(3):437-444.
30. Yang Y-L, Jaing T-H, Chen S-H, et al. Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan. Scientific Reports. 2021;11(1):5893.
31. Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020;136(16):1803-1812.